From the 1Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California; 2Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Women's Hospital, University of Pittsburgh, Pittsburgh Pennsylvania; 3Division for Research and Education in Complementary and Integrative Medical Therapies, Harvard Medical School, Boston, Massachusetts; 4Obstetrics, Gynecology & Reproductive Biology, Harvard Medical School & Brigham and Women's Hospital and Planned Parenthood League of Massachusetts, Boston, Massachusetts.
Funded by the Bixby Center for Reproductive Health Research & Policy and the National Institute of Health through the San Francisco General Hospital General Clinical Research Center.
The authors thank Neal Benowitz, MD, Professor, Department of Clinical Pharmacy, University of California, San Francisco for assistance with pharmacokinetic analysis and Peter Bacchetti, PhD, Department of Epidemiology & Biostatics and Alan Bostrom for statistical analysis.
Corresponding author: Karen R. Meckstroth, MD, MPH, San Francisco General Hospital, Ward 6D, 1001 Potrero Avenue, San Francisco, CA 94110; e-mail: [email protected]